REPL - Replimune Group Inc Profile, Share Price, Market Analysis, Charts, Fundamentals

Company Name, Ticker, Industry, else..

Replimune Group Inc (REPL)

Other Ticker:

Sector • Healthcare Industry • Biotechnology & Pharmaceuticals

Industry • Biotechnology & Pharmaceuticals

Sector • Healthcare

Price: $11.0300 $0.57

5.449%

Day's High:	$11.18	Week Perf:	6.36 %
Day's Low:	$ 10.30	30 Day Perf:	9.1 %
Volume (M):	700	52 Wk High:	$ 17.89
Volume (M$):	$ 7,723	52 Wk Avg:	$9.42
Open:	$10.40	52 Wk Low:	$4.92

REPL Charts & Quotes

REPL Charts & Quotes

Company's Segments

Market Capitalization (Millions $)	763
Shares Outstanding (Millions)	69
Employees	-
Revenues (TTM) (Millions $)	-
Net Income (TTM) (Millions $)	-220
Cash Flow (TTM) (Millions $)	45
Capital Exp. (TTM) (Millions $)	7

Replimune Group Inc
Replimune Group Inc is a biotechnology company that specializes in the development of oncolytic immunotherapies to treat various forms of cancer. They have developed a platform called Immulytic that combines multiple engineering strategies to enhance the selective replication of viruses within tumors, ultimately leading to the destruction of cancer cells. The company aims to provide better treatment options for patients by harnessing the power of the immune system to fight cancer. Replimune Group Inc is based in Woburn, Massachusetts and was founded in 2015.

Company Address: 500 Unicorn Park Drive Woburn 1801 MA
Company Phone Number: 222-9600 Stock Exchange / Ticker: NASDAQ REPL

Reports on Competition

List of Competitors

Competitors by Segment

Segment Growth

Growth Rates

Suppliers At a Glance

List of Suppliers

Suppliers Performance

Stock Performances by Major Competitors

5 Days	Decrease / Increase

• View Complete Report

Replimune Group Inc News

Clinical Study

Replimunes RP1 and Nivolumab Combo Demonstrates Promising Results in Anti-PD1 Resistant Melanoma Insights from the E...

Published Sun, Sep 15 2024 1:45 PM UTC

'Replimune?s RP1 Shows Promise in Anti-PD1 Resistant Melanoma, Sets New Benchmarks'Replimune Group Inc made a significant splash at the European Society for Medical Oncology (ESMO) Congress 2024, presenting the primary analysis data from their IGNYTE clinical trial involving RP1 in combination with nivolumab. The data unveils groundbreaking results, especially for melanoma p...

Management Announcement

Replimune Group Inc Gains FDA Alignment for RP1 Accelerated Approval Pathway, Inspiring 11.54% Share Price Surge in Q3 2024,

Published Mon, Sep 9 2024 12:00 PM UTC

Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024
- Alignment with FDA on accelerated approval pathway for RP1 in anti-PD1 failed melanoma
- Share price increases by 11.54% in Q3 of 2024
- Cumulative net loss of $-220 million with a negative return on assets
- Ranking improves to 3241 in overall ROA ranking...

Clinical Study

Replimunes IGNYTE Trial Gains Spotlight at ESMO 2024 A Step Forward in Oncolytic Immunotherapy

Published Thu, Aug 22 2024 12:00 PM UTC

In a significant development in the realm of cancer treatment, Replimune Group, Inc. has announced that their late-breaking abstract presenting the primary analysis of the IGNYTE clinical trial has been selected for an oral presentation at the prestigious European Society for Medical Oncology (ESMO) Congress 2024. This eagerly awaited event is set to take place from Septembe...

Clinical Study

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Published Tue, Aug 13 2024 12:00 PM UTC

Innovative Step Forward: Replimune's New Clinical Trial Sets the Stage for Advanced Melanoma Treatment'By 'Replimune Group Inc., a pioneering biotech company specializing in oncolytic immunotherapies, has marked a significant milestone in its quest to revolutionize cancer treatment. The company recently announced the dosing of the first patient in its IGNYTE-3 clinical tria...

Stocks on the Move

s on June 6, 2024, when it announced promising outcomes from its IGNYTE clinical trial. The trial demonstrated encouraging results, with one-third of melanoma patients experienc...

Published Sat, Jun 29 2024 4:33 PM UTC

Replimune Group Inc (NASDAQ: REPL) has recently witnessed a significant surge in its stock performance, surpassing the broader market's gains. This article examines the events that have contributed to Replimune Group's upward trajectory and analyzes the company's prospects in light of recent developments.Replimune Group Inc (NASDAQ: REPL) shares have been outperforming the m...

REPL's Valuation	Current
Price to Earnings PE Ratio (TTM)	-
Price to Earnings PE Ratio (Expected)	-
Price to Sales (TTM)	-
Price to Sales (Expected)	-
Price to Book	1.79
PEG (TTM)	-

REPL's Financial Strength	Current
Quick Ratio	13.15
Working Capital Ratio	13.46
Leverage Ratio (MRQ)	0.25
Total Debt to Equity	0.11
Interest Coverage (TTM)	-
Debt Coverage (TTM)	-

Per Share	Current
Earnings (TTM)	-3.18 $
Revenues (TTM)	-
Cash Flow (TTM)	0.65 $
Cash	6.78 $
Book Value	6.16 $
Dividend (TTM)	0 $

REPL's Efficiency	Current
Revenue per Employee (TTM)	-
Net Income per Employee (TTM)	-
Receivable Turnover Ratio (TTM)	-
Inventory Turnover Ratio (TTM)	-
Asset Turnover Ratio (TTM)	-

REPL's Profitability Ratios	Current
Gross Margin (MRQ)	-
Operating Margin (MRQ)	-
Net Margin (MRQ)	-
Net Cash Flow Margin (MRQ)	-
Effective Tax Rate (TTM)	-

Management Effectiveness	Current
Return On Assets (TTM)	-
Return On Investment (TTM)	-
Return On Equity (TTM)	-
Dividend Yield	-
Pay out Ratio (TTM)	-

REPL's Valuation
Price to Earnings PE Ratio (TTM)	-
Price to Earnings PE Ratio (Expected)	-
Price to Sales (TTM)	-
Price to Sales (Expected)	-
Price to Book	1.79
PEG (TTM)	-

Per Share
Earnings (TTM)	-3.18 $
Revenues (TTM)	-
Cash Flow (TTM)	0.65 $
Cash	6.78 $
Book Value	6.16 $
Dividend (TTM)	0 $

REPL's Financial Strength
Quick Ratio	13.15
Working Capital Ratio	13.46
Leverage Ratio (MRQ)	0.25
Total Debt to Equity	0.11
Interest Coverage (TTM)	-
Debt Coverage (TTM)	-

REPL's Efficiency
Revenue per Employee (TTM)	-
Net Income per Employee (TTM)	-
Receivable Turnover Ratio (TTM)	-
Inventory Turnover Ratio (TTM)	-
Asset Turnover Ratio (TTM)	-

REPL's Profitability Ratio
Gross Margin (MRQ)	-
Operating Margin (MRQ)	-
Net Margin (MRQ)	-
Net Cash Flow Margin (MRQ)	-
Effective Tax Rate (TTM)	-

Management Effectiveness
Return On Assets (TTM)	-41.56 %
Return On Investment (TTM)	-44.82 %
Return On Equity (TTM)	-52.15 %
Dividend Yield	-
Pay out Ratio (TTM)	-

Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright � 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

REPL Company Profile

Replimunes RP1 and Nivolumab Combo Demonstrates Promising Results in Anti-PD1 Resistant Melanoma Insights from the E...

Replimune Group Inc Gains FDA Alignment for RP1 Accelerated Approval Pathway, Inspiring 11.54% Share Price Surge in Q3 2024,

Replimunes IGNYTE Trial Gains Spotlight at ESMO 2024 A Step Forward in Oncolytic Immunotherapy

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

s on June 6, 2024, when it announced promising outcomes from its IGNYTE clinical trial. The trial demonstrated encouraging results, with one-third of melanoma patients experienc...